Literature DB >> 21098971

Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.

Lorena Rami1, Juan Fortea, Beatriz Bosch, Cristina Solé-Padullés, Albert Lladó, Alex Iranzo, Raquel Sánchez-Valle, Jose Luis Molinuevo.   

Abstract

The objective was to study the association between cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)(1-42), t-tau, and p-tau and cognitive performance along the Alzheimer's disease (AD) continuum from healthy subjects to AD patients and, specifically, among patients in the pre-dementia stage of the disease. A total of 101 subjects were studied: 19 healthy controls (CTR), 17 subjects with subjective memory complaints (SMC), 47 with mild cognitive impairment (MCI), and 18 AD patients. Only memory performance significantly correlated with CSF levels of Aβ(1-42), t-tau, and p-tau along the AD continuum. Subgroup analyses revealed that in SMC patients Aβ(1-42) levels positively correlated with the total recall score of the Free and Cued Selective Reminding Test (FCRST) (r = 0.666; p < 0.005), Digit Span (r = 0.752; p < 0.005), and CERAD world list learning (r = 0.697; p < 0.005). In MCI patients, a significant inverse correlation was found between the word list recall score from the CERAD and t-tau (r = -0.483; p < 0.005) and p-tau levels (r = -0.495; p < 0.005), as well as between the total recall subtest score from the FCRST and both t-tau (r = -0.420; p < 0.005) and p-tau levels (r = -0.422; p < 0.005). No significant correlations were found between other aspects of cognition and CSF levels in CTR or AD patients. These results indicate that memory performance is related to Aβ(1-42) levels in SMC, while it is associated with tau in the prodromal stage of the disease. This suggests that in the continuum from healthy aging to AD, memory performance is first related with Aβ(1-42) levels and then with t-tau or p-tau, before becoming independent of biomarker levels in the dementia stage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21098971     DOI: 10.3233/JAD-2010-101422

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  23 in total

Review 1.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

2.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 3.  Brain aging, Alzheimer's disease, and mitochondria.

Authors:  Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-09-02

4.  The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease.

Authors:  Raquel Lemos; Diana Duro; Mário R Simões; Isabel Santana
Journal:  Arch Clin Neuropsychol       Date:  2014-07-25       Impact factor: 2.813

Review 5.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease.

Authors:  Frank Jessen; Rebecca E Amariglio; Martin van Boxtel; Monique Breteler; Mathieu Ceccaldi; Gaël Chételat; Bruno Dubois; Carole Dufouil; Kathryn A Ellis; Wiesje M van der Flier; Lidia Glodzik; Argonde C van Harten; Mony J de Leon; Pauline McHugh; Michelle M Mielke; Jose Luis Molinuevo; Lisa Mosconi; Ricardo S Osorio; Audrey Perrotin; Ronald C Petersen; Laura A Rabin; Lorena Rami; Barry Reisberg; Dorene M Rentz; Perminder S Sachdev; Vincent de la Sayette; Andrew J Saykin; Philip Scheltens; Melanie B Shulman; Melissa J Slavin; Reisa A Sperling; Robert Stewart; Olga Uspenskaya; Bruno Vellas; Pieter Jelle Visser; Michael Wagner
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

6.  Two-stage screening for early dementia in primary care.

Authors:  Ellen Grober; Wenzhu Bi Mowrey; Amy R Ehrlich; Peter Mabie; Steven Hahn; Richard B Lipton
Journal:  J Clin Exp Neuropsychol       Date:  2016-06-07       Impact factor: 2.475

7.  Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

Authors:  Corinne Pettigrew; Anja Soldan; Abhay Moghekar; Mei-Cheng Wang; Alden L Gross; Richard O'Brien; Marilyn Albert
Journal:  Neuropsychologia       Date:  2015-09-21       Impact factor: 3.139

8.  CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

Authors:  Michael Ewers; Philip Insel; William J Jagust; Leslie Shaw; John Q Trojanowski; Paul Aisen; Ronald C Petersen; Norbert Schuff; Michael W Weiner
Journal:  Cereb Cortex       Date:  2011-10-29       Impact factor: 5.357

9.  Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults.

Authors:  Kylie H Alm; Andreia V Faria; Abhay Moghekar; Corinne Pettigrew; Anja Soldan; Susumu Mori; Marilyn Albert; Arnold Bakker
Journal:  Neurobiol Aging       Date:  2019-11-21       Impact factor: 4.673

Review 10.  Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments.

Authors:  Jennifer N Vega; Paul A Newhouse
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.